• 1
    Janjan NA, Payne R, Gillis T, et al. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage. 1998; 16: 171-178.
  • 2
    Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998; 16: 3890-3899.
  • 3
    Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004; 9: 687-695.
  • 4
    Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994; 330: 592-596.
  • 5
    Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004; 111: 306-312.
  • 6
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7: 377-387.
  • 7
    Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100: 2613-2621.
  • 8
    Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458-1468.
  • 9
    Wong R, Wiffen P. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;( 2): CD002068.
  • 10
    Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 5132-5139.
  • 11
    Zometa (zoledronic acid) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
  • 12
    Cleeland C. The Brief Pain Inventory User Guide. Houston, TX: The University of Texas M. D. Anderson Cancer Center; 2009.
  • 13
    Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61: 277-284.
  • 14
    Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a 4 country sample: new information from multidimensional scaling. Pain. 1996; 67: 267-273.
  • 15
    Chung K, Barlev A, Braun A, Qian Y, Zagari M. Development of the Analgesic Quantification Algorithm (AQA): a new scale to assess analgesic use. Poster presented at: Joint 15th Congress of the European Cancer Organization and 34th Congress of the European Society for Medical Oncology; September 20-24, 2009; Berlin, Germany.
  • 16
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989; 10: 407-415.
  • 17
    Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008; 9: 105-121.
  • 18
    Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K. Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol. 2011; 9: 72-78.
  • 19
    Lemay K, Wilson KG, Buenger U, et al. Fear of pain in patients with advanced cancer or in patients with chronic noncancer pain. Clin J Pain. 2011; 27: 116-124.
  • 20
    Turk DC, Sist TC, Okifuji A, et al. Adaptation to metastatic cancer pain, regional/local cancer pain and non-cancer pain: role of psychological and behavioral factors. Pain. 1998; 74: 247-256.
  • 21
    Wang XS, Cleeland CS, Mendoza TR, et al. The effects of pain severity on health-related quality of life: a study of Chinese cancer patients. Cancer. 1999; 86: 1848-1855.
  • 22
    Zhukovsky DS, Gorowski E, Hausdorff J, Napolitano B, Lesser M. Unmet analgesic needs in cancer patients. J Pain Symptom Manage. 1995; 10: 113-119.
  • 23
    van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in the Netherlands. Pain. 2007; 132: 312-320.
  • 24
    Diel IJ, Kurth AH, Sittig HB, et al. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate—results from a post-marketing surveillance study. Support Care Cancer. 2010; 18: 1305-1312.
  • 25
    Goblirsch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clin Cancer Res. 2006; 12( 20 pt 2) 6231s-6235s.
  • 26
    von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer. 2008; 16: 1105-1115.
  • 27
    Yoneda T, Hata K, Nakanishi M, et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone. 2011; 48: 100-105.